Biochemical and genetic control of apoptosis: Relevance to normal hepatopoiesis and hematological malignancies

Blood

Volumn 93, Issue 11, 1999, Pages 3587-3600

  Wickremasinghe, R Gitendra ^a   Hoffbrand, A Victor ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN BCL 2; PROTEIN P53;

APOPTOSIS; BIOCHEMISTRY; CAENORHABDITIS ELEGANS; CHROMOSOME TRANSLOCATION; GENETIC REGULATION; HEMATOPOIESIS; HUMAN; LEUKEMIA; LYMPHOMA; NONHUMAN; ONCOGENE; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; REVIEW; TUMOR SUPPRESSOR GENE;

EID: 0033152340     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v93.11.3587     Document Type: Review

References (189)

1. Fisher DE: Apoptosis in cancer therapy: Crossing the threshold. Cell 78:539, 1994
2. Hannun YA: Apoptosis and the dilemma of cancer chemotherapy. Blood 89:1845, 1997
3. Kerr JFR, Winterford CM, Harmon BV: Apoptosis: Its significance in cancer and cancer therapy. Cancer 73:2013, 1994
4. Fadok VA, Voelker DR, Campbell PA, Cohen JJ, Bratton DL, Henson PM: Exposure of phosphatidylserine on the surface of apoptotic lymphocytes triggers specific recognition and removal by macrophages. J Immunol 148:2207, 1992
5. Martin SJ, Reuterlingsperger CP, McGahon AJ, Rader JA, van Schie RC, LaFace DM, Green DR: Early redistribution of plasma membrane phosphatidylserine is a general feature of apoptosis regardless of the initiating stimulus: Inhibition by overexpression of bcl-2 and abl. J Exp Med 182:1545, 1995
6. Hengartner MO, Horvitz HR: Programmed cell death in Caenorhabditis elegans. Curr Opin Genet Dev 4:581, 1994
7. Hengartner MO, Horvitz HR: C. elegans cell-survival gene ced-9 encodes a functional homolog of the mammalian proto-oncogene bcl-2. Cell 76:665, 1994
8. Vaux DL, Weissman IL, Kim SK: Prevention of programmed cell death in Caenorhabditis elegans by human bcl-2. Science 258:1955, 1992
9. Huang DCS, Adams JM, Cory S: The conserved N-terminal BH4 domain of bcl-2 homologues is essential for inhibition of apoptosis and interaction with CED-4. EMBO J 17:1029, 1998
10. Thornberry NA, Lazebnik Y: Caspases: Enemies within. Science 281:12, 1998
11. Green DR, Reed JC: Mitochondria and apoptosis. Science 281:1309, 1998
12. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin T-T, Yu V, Miller DK: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376:37, 1995
13. Tewari M, Quan LT, O'Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM: Yama/CPP32β, a mammalian homolog of ced-3, is crmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81:801, 1995
14. Kothakota S, Azuma T, Reinhard C, Klippel A, Tang J, Chu K, McGarry TJ, Kirschner MW, Koths K, Kwiatowski DJ, Williams LT: Caspase 3-generated fragment of gelsolin: Effector of morphological changes in apoptosis. Science 278:294, 1997
15. Liu X, Zou H, Slaughter C, Wang X: DFF, a heterodimeric protein that functions downstream of caspase 3 to trigger DNA fragmentation during apoptosis. Cell 89:175, 1997
16. Orth K, Chinnaiyan AM, Garg M, Froelich CJ, Dixit VM: The ced-3/ICE-like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. J Biol Chem 271:16443, 1996
17. Roy N, Devereaux QL, Takahashi R, Salvesen GS, Reed JC: The cIAP-1 and c-IAP-2 proteins are direct inhibitors of specific caspases. EMBO J 16:6914, 1997
18. Vucic D, Kaiser WJ, Miller LK: Inhibitor of apoptosis oroteins physically infract with and block apoptosis induced by Drosophila proteins HID and GRIM. Mol Cell Biol 18:3300, 1998
19. Ashkenazi A, Dixit VM: Death receptors: Signaling and modulation. Science 281:1305, 1998
20. Chinnaiyan AM, O'Rourke K, Tewari M, Dixit VM: FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis. Cell 81:505, 1995
21. Muzio M, Chinnaiyan AM, Kischkel FC, O'Rourke K, Shevchenko A, Ni J, Scaffidi C, Bretz JD, Zhang M, Gentz R Mann M, Krammer PH, Peter ME, Dixit VM: FLICE, a novel FADD-homologous ICE/CED-3-like protease, is recruited to the CD95 (Fas/apo-1) death-inducing signaling complex. Cell 85:817, 1996
22. Boldin MP, Goncharov TM, Goltsev YV, Wallach D: Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/Apo-1 and TNF receptor-induced cell death. Cell 85:803, 1996
23. Berke G: The CTL's kiss of death. Cell 81:9, 1995
24. Darmon AJ, Nicholson DW, Bleackley RC: Activation of the apoptotic protease CPP32 by cyotoxic T cell-derived granzyme B. Nature 377:446, 1995
25. Martin SJ, Amarantes-Mendes GP, Shi L, Chuang TH, Casiano CA, O'Brien GA, Fitzgerald P, Tan EM, Bokoch GM, Greenberg AM, Green DR: The cytotoxic cell protease granzyme B initiates apoptosis in a cell-free system by proteolytic processing and activation of the ICE/CED-3 family protease CPP32 via a novel two-step mechanism. EMBO J 15:2407, 1996
26. Froelich CJ, Dixit VM, Yang X: Lymphocyte granule-mediated apoptosis: Matters of viral mimicry and deadly proteases. Immunol Today 19:30, 1998
27. Moretta A: Molecular mechanisms in cell-mediated cytotoxicity. Cell 90:13, 1997
28. Vaux DL, Cory S, Adams JM: Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 335:440, 1988
29. Tsujimoto Y: Stress-resistance conferred by high levels of bcl-2α protein in human B lymphoblastoid cell. Oncogene 4:1331, 1989
30. Yang E, Korsmeyer SJ: Molecular thanatopsis: A discourse on the bcl-2 family. Blood 88:386, 1996
31. L, an inhibitor of programmed cell death. Nature 381:335, 1996
32. L-Bak peptide complex: Recognition between regulators of apoptosis. Science 275:983, 1997
33. Oltvai ZN, Korsmeyer SJ: Checkpoints of duelling dimers foil death wishes. Cell 79:189, 1994
34. Hsu Y-T, Youle RJ: Nonionic detergents induce dimerization among members of the bcl-2 famly. J Biol Chem 272:13829, 1997
35. Knudson CM, Korsmeyer SJ: Bcl-2 and Bax function independently to regulate cell death. Nat Genet 16:358, 1997
36. Simonian PL, Grillot DAM, Andrews DW, Leber B, Nunez G: Bax homodimerization is not required for bax to accelerate chemotherapy-induced cell death. J Biol Chem 271:32073, 1996
37. Chen-Leavy Z, Cleary ML: Membrane topology of the Bcl-2 proto-oncogenic protein demonstrated in vitro. J Biol Chem 265:4929, 1990
38. Monaghan P, Robertson D, Amos TA, Dyer MJ, Mason DY, Greaves MF: Ultrastructural localization of bcl-2 protein. J Histochem Cytochem 40:1819, 1992
39. Wolter KG, Hsu Y-T, Smith CL, Nechushtan A, Xi X-G, Youle RJ: Movement of bax from cytosol to mitochondria during apoptosis. J Cell Biol 139:1281, 1997
40. Zou H, Henzel WJ, Liu X, Lutschg A, Wang X: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase 3. Cell 90:405, 1997
41. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91:479, 1997
42. Srinivasula SM, Ahmad M, Fernades-Alnemri T, Alnemri ES: Autoactivation of pro-caspase 9 by Apaf-1-mediated oligomerization. Molec Cell 1:949, 1998
43. Yang J, Liu X, Bhalla K, Kim CN, Ibrado AM, Cai J, Peng T-I, Jones DP, Wang X: Prevention of apoptosis by bcl-2: Release of cytochrome c from mitochondria blocked. Science 275:1129, 1997
44. Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD: The release of cytochrome c from mitochondria: A primary site for bcl-2 regulation of apoptosis. Science 275:1132, 1997
45. L regulates the membrane potential and volume homeostasis of mitochondria. Cell 91:627, 1997
46. Jurgensmeier JM, Xie Z, Devereaux Q, Ellerby L, Bredesden D, Reed JC: Bax directly induces release of cytochrome c from isolated mitochondria. Proc Natl Acad Sci USA 95:4997, 1998
47. Hengartner MO: Death cycle and Swiss army knives. Nature 391:441, 1998
48. Minn AJ, Velez P, Schendel SL, Liang H, Muchmore SW, Fesik SW, Fill M, Thompson CB: Bcl-xL forms an ion channel in synthetic lipid membranes. Nature 385:353, 1997
49. Schendel SL, Xie Z, Montal MO, Matsuyama S, Montal M, Reed JC: Channel formation by anti-apoptotic protein bcl-2. Proc Natl Acad Sci USA 94:5113, 1997
50. Antonsson B, Conti F, Ciavatta A, Montessuit S, Lewis S, Martinou I, Bernasconi L, Bernard A, Mermod J-J, Mazzei G, Maundrell K, Gambale F, Sadoul R, Martinou J-C: Inhibition of bax channel-forming activity by bcl-2. Science 277:370, 1997
51. Marchetti P, Castedo M, Susin SA, Zamzami N, Hirsch T, Macho A, Haeffner A, Hirsch F, Geuskens M, Kroemer G: Mitochondrial permeability transition is a central coordinating event of apoptosis. J Exp Med 184:1155, 1996
52. L antagonize the mitochondrial dysfunction preceding nuclear apoptosis induced by chemotherapeutic agents. Cancer Res 57:62, 1997
53. Shimizu S, Eguchi Y, Kamiike W, Funahashi Y, Mignon A, Lacronique V, Matsuda H, Tsujimoto Y: Bcl-2 prevents apoptotic mitochondrial dysfunction by regulating proton flux. Proc Natl Acad Sci USA 95:1455, 1998
54. Rosse T, Olivier R, Monney L, Rager M, Conus S, Fellay I, Jansen B, Borner C: Bcl-2 prolongs cell survival after bax-induced release of cytochrome c. Nature 391:496, 1998
55. Zhivotovsky B, Orrenius, S, Brustugun OT, Doskeland SO: Injected cytochrome c induces apoptosis. Nature 391:449, 1998
56. L interacts with Apaf-1 and inhibits Apaf-1-dependent caspase 9 activation. Proc Natl Acad Sci USA 95:4386, 1998
57. Chinnaiyan AM, O' Rourke K, Lane BR, Dixit VM: Interaction of ced-4 with ced-3 and ced-9: A molecular framework for cell death. Science 275:1122, 1997
58. Marzo I, Susin SA, Petit PX, Ravagnan L Brenner C, Larochette N, Zamzami N, Kroemer G: Caspases disrupt mitochondrial membrane barrier function. FEBS Lett 427:198, 1998
59. L. Cell 87:619, 1996
60. del Peso L, Gonzalez-Garcia, M, Page C, Herrera R, Nunez G: Interleukin 3-induced phosphorylation of BAD through protein kinase Akt. Science 278:687, 1997
61. Datta SR, Dudek H, Tao X, Masters S Fu H, Gotoh Y, Greenberg ME: Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery Cell 91:231, 1997
62. Hemmings BA: Akt signaling: Linking membrane events to life and death decisions. Science 275:628, 1997
63. Levine AJ: p53, the cellular gatekeeper for growth and cell division. Cell 88:323, 1997
64. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, Plunkett BS, Vogelstein B, Fornace AJ: A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia telangiectasia. Cell 71:587, 1992
65. Lee S, Elenbaas B, Levine AJ, Griffith J: p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell 81:1013, 1995
66. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362:847, 1993
67. Clarke AR, Purdie CA, Harrison DJ, Morris, RG, Bird CC, Hooper ML, Wyllie AH: Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 362:849, 1993
68. Miyashita T, Reed JC: Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80:293, 1995
69. Miyashita T, Krajewski S, Krajewska M, Wang H-G, Lin HK, Liebermann DA, Hoffman B, Reed JC: Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9:1799, 1994
70. McCurrach ME, Connor TMF, Knudson CM, Korsmeyer SJ, Lowe SW: Bax-deficiency promotes drug resistance and oncogenic transformation by attenuating p53-dependent apoptosis. Proc Natl Acad Sci USA 94:2345, 1997
71. Brady HJM, Salomons GS, Bobeldijk RC, Berns AJM: T cells from baxα transgenic mice show accelerated apoptosis in response to stimuli but do not show restored DNA damage-induced cell death in he absence of p53. EMBO J 15:1221, 1996
72. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B: A model for p53-induced apoptosis. Nature 389:300, 1997
73. Zamzami N, Susin SA, Marchetti P, Hirsch, T, Gomez-Monterrey I, Castedo M, Kroemer, G: Mitochondrial control of nuclear apoptosis. J Exp Med 183:1533, 1996
74. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T: Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci USA 93:11848, 1996
75. Jacobson MD, Raff MC: Programmed cell death and bcl-2 protection in very low oxygen. Nature 374:814, 1995
76. Muschel RJ, Bernhard EJ, Garza L, McKenna WG, Koch CJ: Induction of apoptosis at different oxygen tensions: Evidence that oxygen radicals do not mediate apoptotic signaling. Cancer Res 55:995, 1995
77. Shen Y, Shenk T: Relief of p53-mediated transcriptional repression by the adenovirus E1B 19 kDa protein or the cellular bcl-2 protein. Proc Natl Acad Sci USA 91:8940, 1994
78. Caelles C, Helmberg A, Karin M: p53-dependent apoptosis in the absence of transcriptional activation of p53 target genes. Nature 370:220, 1994
79. Dubrez L, Goldwasser F, Genne P, Pommier Y, Solary E: The role of cell cycle regulation and apoptosis triggerring in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia 9:1013, 1995
80. Santana P, Pena LA, Haimovitz-Friedman A, Martin S, Green D, McLaughlin M, Schuchman EH, Fuks Z, Kolesnick R: Acid sphingomyelinase-deficient human lymphoblasts are defective in radiation-induced apoptosis. Cell 86:189, 1996
81. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T: p53 status and the efficacy of cancer therapy in vivo. Science 266:807, 1994
82. Zhan Q, Fan S, Bae I, Guillof C, Liebermann DA, O' Connor PM, Fornace AJ: Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9:3743, 1995
83. Jost CA, Marin MC, Kaelin WG: p73 is a human p53-related protein that can induce apoptosis. Nature 389:191, 1997
84. Sachs L: The control of hematopoiesis and leukemia: From basic biology to the clinic. Proc Natl Acad Sci USA 93:4742, 1996
85. 0 and entry into the cell cycle of primitive human hemopoietic progenitors. Proc Natl Acad Sci USA 89:4013, 1992
86. - bone marrow cells with multilineage potential at the single cell level: Key role of thrombopoietin. Blood 90:2282, 1997
87. Brandt JE, Bhalla K, Hoffman R: Effects of interleukin-3 and c-kit ligand on the survival of various classes of human hematopoietic progenitor cells. Blood 83:1507, 1994
88. Muench MO, Roncarolo MG, Menon S, Xu Y, Kastelein R Zurawski S, Hannum CH, Culpepper J, Lee F, Namikawa R: FLK-2/ FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver. Blood 85:963, 1995
89. Veiby OP, Jacobsen FW, Cui L, Lyman SD, Jacobsen SE: The flt3 ligand promotes the survival of primitive hemopoietic progenitor cells with myeloid as well as B lymphoid potential. Suppression of apoptosis and counteraction by TNF α and TGF-β. J Immunol 157:2953, 1996
90. Seleri C, Maciejewski JP, Sato T, Young NS: Interferons-γ constitutively expressed in the stromal microenvironement of human marrow cultures mediates potent hematopoietic inhibition. Blood 87:4149, 1996
91. + human marrow cells is induced by interferon γ and tumor necrosis factor a and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood 85:3183, 1995
92. Manabe A, Murti KG, Coustan-Smith E, Kumagai M-A, Behm FG, Raimondi SC, Campana D: Adhesion-dependent survival of normal and leukemic human B lymphoblasts on bone marrow stromal cells. Blood 83:758, 1994
93. Murti KG, Brown PS, Kumagai M-A, Campana D: Molecular interactions between B-cell progenitors and the bone marrow microenvironement. Exp Cell Res 226:47, 1996
94. Lotem J, Sachs L: Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82:1092, 1993
95. Blandino G, Scardigli R, Rizzo MG, Crescenzi M, Soddu S, Sacchi A: Wild-type p53 modulates apoptosis of normal, IL-3 deprived hematopoietic cells. Oncogene 10:731, 1995
96. Lotem J, Sachs L: Hematopoietic cytokines inhibit apoptosis induced by transforming growth factor β1 and cancer chemotherapy compounds in myeloid leukemic cells. Blood 80:1750, 1992
97. Lotem J, Sachs L: Interferon-γ inhibits apoptosis induced by wild-type p53, cytotoxic anticancer agents and viability factor deprivation in myeloid cells. Leukemia 9:685, 1995
98. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M: Wild-type p53 induces apoptosis of myelod leukaemic cells that is inhibited by interleukin-6. Nature 352:345, 1991
99. Nunez G, Merino R, Grillot D, Gonzalez-Garcia M: Bcl-2 and Bcl-x: Reglatory switches for lymphoid death and survival. Immunol Today 15:582, 1994
100. Dubrez L, Savoy I, Hamman A, Solary E: Pivotal role of a DEVD-sensitive step in etoposide-induced and fas-mediated apoptotic pathways. EMBO J 15:5504, 1996
101. Datta R, Banach D, Kojima H, Talanian RV, Alnemri ES, Wong WW, Kufe DW: Activation of the CPP32 protease in apoptosis induced by 1-β-D arabinofuranosylcytosine and other DNA-damaging agents. Blood 88:1936, 1996
102. Belosillo B, Dalmau M, Colomer D, Gil J: Involvement of CED-3/ICE proteases in the apoptosis of B-chronic lymphocytic leukaemia cells. Blood 89:3378, 1997
103. Seto M, Jaeger U, Hockett RD, Graninger W, Bennett S, Goldman P, Korsmeyer SJ: Alternative promoters and exons, somatic mutation and deregulation of the bcl-2-Ig fusion gene in lymphoma. EMBO J 7:123, 1988
104. Petrovic AS, Young RL, Hilgarth B, Ambros P, Korsmeyer SJ, Jaeger U: The Ig heavy chain 3′ end confers a posttranscriptional processing advantage to bcl-2-Igh fusion RNA in t(14;18) lymphoma. Blood 91:3952, 1998
105. McDonell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP, Korsmeyer SJ: bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57:79, 1989
106. Strasser A, Harris AW, Bath ML, Cory S: Novel primitive lymphoid tumours induced in transgenic mice by cooperation between myc and bcl-2. Nature 348:331, 1990
107. Miyashita T, Reed JC: Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151, 1993
108. Miyashita T, Reed JC: bcl-2 gene transfer increases relative resistance of S49.1 and WEHI7.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 52:5407, 1992
109. L can confer a multidrug resistant phenotype. Blood 86:1903, 1995
110. Rohatiner A, Lister TA: Management of follicular lymphoma. Curr Opin Oncol 6:473, 1994
111. Ghia P, Boussiotis VA, Schultze JL, Cardodo AA, Dorfman DM, Gribben JG, Freedman AS, Nadler LM: Unbalanced expression of bcl-2 family proteins in follicular lymphoma: Contribution of CD40 signalling in promoting survival. Blood 91:244, 1998
112. Webb A, Cunningham D, Cotter F, Clarke PA, di Stefano F, Ross P, Corbo M, Dziewanowska Z: Bcl-2 antisense therapy in patients with non-Hodgkin's lymphoma. Lancet 349:1137, 1997
113. Plumas J, Jacob M-C, Chaperot L, Molens JP, Sotto J-J, Bensa J-C: Tumor B cells from non-Hodgkin's lymphoma are resistant to CD95 (Fas/apo-1) mediated apoptosis. Blood 91:2875, 1998
114. Foon KA, Rai KR, Gale RP: Chronic lymphocytic leukemia: New insights into biology and therapy. Ann Intern Med 113:525, 1990
115. Dyer MJS, Zani VJ, Lu WZ, O'Byrne A, Mould S, Chapman R, Heward JM, Kayano H, Jadayel D, Matutes E, Catovsky, D, Oscier DG: Bcl-2 translocations in leukemias of mature B cells. Blood 83:3682, 1994
116. Thomas A, El Rouby S, Reed JC, Krajewski S, Silber R, Potmesil M, Newcomb EW: Drug-induced apoptosis in B-cell chronic lymphocytic leukemia: Relationship between p53 gene mutations and bcl-2/bax proteins in drug resistance. Oncogene 12:1055, 1996
117. Pepper C, Hoy T, Bentley DP: Bcl-2/bax ratios in chronic lymphocytic leukaemia and their correlation with in vitro and clinical drug resistance. Br J Cancer 76:935, 1997
118. Panayiotidis P, Ganeshaguru K, Jabbar SAB, Hoffbrand AV: Interleukin-4 inhibits apoptotic cell death and loss of bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro. Br J Haematol 85:439, 1993
119. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M: Interleukin-4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates bcl-2 expression. J Exp Med 176:1319, 1992
120. Panayiotidis P, Ganeshaguru K, Jabbar SAB, Hoffbrand AV: Alpha interferon (α-IFN) protects B-chronic lymphocytic leukaemia cells from apoptotic death in vitro. Br J Haematol 86:169, 1994
121. Jewell AP, Lydyard PM, Worman CA, Giles FJ, Goldstone AH: Growth factors can protect B-chronic lymphocytic leukaemia cells against programmed cell death without promoting proliferation. Leuk Lymphoma 18:159, 1995
122. Buschle M, Campana D, Carding SR, Richard C, Hoffbrand AV, Brenner MK: Interferon-γ inhibits apoptotic cell death in B chronic lymphocytic leukemia. J Exp Med 177:213, 1993
123. Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand AV: Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol 92:97, 1996
124. Lagneaux L, Delforge A, Bron D, De Bruyn C, Stryckman P: Chronic lymphocytic leukemic B cells but not normal B cells are rescued from apoptosis by contact with normal bone marrow stromal cells. Blood 91:2387, 1998
125. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, Wang H-G, Zhang X, Bullrich F, Croce CM, Rai K, Hines J, Reed JC: Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: Correlations with in vitro and in vivo chemoresponses. Blood 91:3379, 1998
126. Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, Archimbaud E, Magaud J-P, Guyotat D: High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 81:3091, 1993
127. Maung ZT, MacLean FR, Reid MM, Pearson ADJ, Proctor SJ, Hamilton PJ, Hall AG: The relAtionship between bcl-2 expression and response to chemotherapy in acute leukaemia. Br J Haematol 88:105, 1994
128. Banker DE, Groudine M, Norwood T, Appelbaum FR: Measurement of spontaneous and therapeutic agent-induced apoptosis with bcl-2 protein expression in acute myeloid leukemia. Blood 89:243, 1997
129. Kaufmann SH, Karp JE, Svingen PA, Krajewski S, Burke PJ, Gore SD, Reed JC: Elevated expression of the apoptotic regulator Mcl-I at the time of leukemic relapse. Blood 91:991, 1998
130. Keith FJ, Bradbury DA, Zhu Y-M, Russell NH: Inhibition of bcl-2 with antisense oligonucleotides induces apoptosis and increases the sensitivity of AML blasts toAra-C. Leukemia 9:131, 1995
131. Campos L, Sabido O, Sebban C, Charrin C, Bertheas MF, Fiere D, Guyotat D: Expression of the bcl-2 proto-oncogene in adult acute lymphoblastic leukemia. Leukemia 10:434, 1996
132. Prokocimer M, Rotter V: Structure and function of p53 in normal cells and their aberrations in cancer cells: Projections on the hematologic cell lineages. Blood 84:2391, 1994
133. Ahuja H, Bar-Eli M, Arlin Z, Advani S, Allen SL, Goldman J, Snyder D, Foti A, Cline M: The spectrum of molecular alterations in the evolution of chronic myelocytic leukemias. J Clin Invest 87:2042, 1991
134. El Rouby S, Thomas A, Costin, D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW: p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452, 1993
135. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervitte I, Morel P, Fenaux P: p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 84:3148, 1994
136. Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T, Vegna ML, Guglielmi C, Mancini F, Giuliacci S, Sacchi A, Mandelli F, Foa R: p53 expression on B-cell chronic lymphocytic leukemia: A marker of disease progression and poor prognosis. Blood 91:4342, 1998
137. Gaidano G, Ballerini P, Gong JZ, Inghirami G, Neri A, Newcomb EW, Magrath IT, Knowles DM, Dalla-Favera R: p53 mutations in human lymphoid malignancies: Association with Burkitt lymphoma and chronic lymphocytic leukemia. Proc Natl Acad Sci USA 88:5413, 1991
138. Sander CA, Yano T, Clark HM, Harris C, Longo DL, Jaffe ES, Raffeld M: p53 mutation is associated with progression in follicular lymphomas. Blood 82:1994, 1993
139. Nakai H, Tanaka S, Nishigaki H, Taniwaki M, Yokota S, Horiike S, Takashima T, Seriu T, Nakagawa H: p53 gene mutation and loss of a chromosome 17p in Philadelphia chromosome (Ph1)-positive acute leukemia. Leukemia 7:1547, 1993
140. Wada M, Bartram CR, Nakamura H, Hachiya M, Chan D-L, Borenstein J, Miller CW, Ludwig L, Hansen-Haggo TE, Ludi WD, Reiter A, Mizoguchi H, Koeffler HP: Analysis of p53 mutations in a large series of lymphoid hematologic malignancies of childhood. Blood 82:3163, 1993
141. Fenaux P, Jonveaux P, Quiquandon I, Lai JL, Pignon JM, Loncheux-Lefebvre MH, Bauters F, Berger R, Kerckaert JP: p53 gene mutations in acute myeloid leukemia with 17p monosomy. Blood 78:1652, 1991
142. Griffin JD, Lowenberg B: Clonogenic cells in acute myeloid leukemia. Blood 68:1185, 1986
143. Zhu Y-M, Bradbury DA, Russell NH: Wild-ype p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br J Cancer 69:468, 1994
144. Kaplinsky C, Lotem J, Sachs L: Protection of human myeloid leukemic cells against doxorubicin-induced apoptosis by granuloctye-macrophage colony-stimulating factor and interleukin 3. Leukemia 10:460, 1996
145. Bischoff JR, Kim DH, Williams A, Heise C, Horn S, Muna M, Ng L, Nye JA, Sampson-Johannes A, Fattaey A, McCormick F: An adenovirus mutant that replicates selectively in p53-deficient human cells. Science 274:342, 1996
146. Taylor AM, Metcalfe JA, Thick J, Mak YF: Leukemia and lymphoma in ataxia telangiectasia. Blood 87:423, 1996
147. Vorechovsky I, Luo L, Dyer MJS, Catovsky D, Amlot PL, Yaxley JC, Foroni L, Hammarstrom L, Webster ADB, Yuille MAR: clustering of missense mutations in the ataxia-telangiectasia gene in a sporadic T-cell leukemia. Nature Genet 17:96, 1997
148. Starostik P, Manshouri T, O'Brien S, Freireich E, Kantarjian H, Haidar M, Lerner S, Keating M, Albitar M: Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Res 58:4552, 1998
149. Stankovic T, Weber P, Stewart G, Bedenham T, Murray J, Byrd PJ, Moss PAH, Taylor AMR: Inactivation of ataxia telangiectasia mutated gene in B-cell chronic lymphocytic leukemia. Lancet 353:26, 1999
150. Riordan FA, Wickremasinghe RG: Signal transduction by the Philadelphia chromosome-encoded BCR/ABL oncoproteins: Therapeutic implications for chronic myeloid leukemia and Philadelphia-positive acute lymphoblastic leukemia. Hematology 1999 (in press)
151. Kurzrock R, Gutterman JU, Talpaz M: The molecular genetics of Philadelphia chromosome-positive leukemia. N Engl J Med 319:990, 1988
152. Yuan Z-M, Huang Y, Ishiko T, Kharbanda S, Weichselbaum RR, Kufe D: Regulation of DNA-damage-induced apoptosis by the c-Abl tyrosine kinase. Proc Natl Acad Sci USA 94:1437, 1997
153. McGahon A, Bissonnette R, Schmitt M, Cotter KM, Green DR, Cotter TM: Bcr-abl maintains resistance of chronic myelogenous leukemia cells to apoptotic cell death. Blood 83:1179, 1994
154. McGahon AJ, Nishioka WK, Martin SJ, Mahboubi A, Cotter TG, Green DR: Regulation of the fas apoptotic cell death pathway by abl. J Biol Chem 270:2625, 1995
155. Bedi A, Zehnbauer BA, Barber JP, Sharkis SJ, Jones RJ: Inhibition of apoptosis by bcr-abl in chronic myeloid leukemia. Blood 83:2038, 1994
156. Amarantes-Mendes G, Kim CN, Liu L, Huang Y, Perkins CL, Green DR, Bhalla K: Bcr-abl exerts its effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase 3. Blood 91:1700, 1998
157. Dubrez L, Eymin B, Sordet O, Droin N, Turhan AG, Solary E: BCR-ABL delays apoptosis upstream of procaspase 3 activation. Blood 91:2415, 1998
158. bcr/abl oncogene activates JL-3/GM-CSF receptor signal transduction pathways in myeloid cell lines. Exp Hematol 21:1010, 1993
159. + ALL involves GTPase activating protein, phospholipase C-γ1 and phosphatidylinositol 3′-kinase. Leukemia 8:115, 1994
160. Skorski T, Bellacosa A, Nieborowska-Skorska M, Majewski M, Martinez R, Choi JK, Trotta R, Wlodarski P, Perrotti D, Chan TO, Wasik MA, Tsichlis PN, Calabretta B: Transformation of hematopoietec cells by BCR/ABL requires activation of a PI-3K/Akt dependent pathway. EMBO J 16:6151, 1997
161. BCR/ABL to the phosphatidylinositol 3′-kinase pathway. Oncogene 12:839, 1996
162. Okabe M, Uehara Y, Miyagishima T, Itaya T, Tanaka M, Kuni-Eda Y, Kurosawa M, Miyazaki T: Effect of herbimycin A, an antagonist of tyrosine kinase, on bcr/abl oncoprotein-associated cell proliferations. Blood 80:1330, 1992
163. Carroll M, Ohno-Jones S, Tamura S, Buchdunger E, Zimmermann J, Lydon NB, Gilliland DG, Druker BJ: CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL and TEL-PDGFR fusion proteins Blood 90:4947, 1997
164. Deininger MW, Goldman JM, Lydon N, Melo JV: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691, 1997
165. Riordan FA, Bravery CA, Mengubas K, Ray N, Borthwick NJ, Akbar AN, Hart SM, Hoffbrand AV, Mehta AB, Wickremasinghe RG: Herbimycin A accelerates the induction of apoptosis following etoposide treatment or γ-irradiation of bcr/abl-positive leukaemia cells. Oncogene 16:1533, 1998
166. O'Brien SG, Kirkland MA, Melo JV, Rao MH, Davidson RJ, McDonald C, Goldman JM: Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines. Leukemia 8:2156, 1994
167. Vaerman, JL, Moureau P, Deldime F, Lewalle P, Lammineur C, Morschhauser F, Martiat P: Antisense oligodeoxyribonucleotides suppress hematologic cell growth through stepwise release of deoxyribonucleotides. Blood 90:331, 1997
168. Look AT: Oncogenic transcription factors in the human acute leukemias. Science 278:1059, 1997
169. μ enhancer of the IgH locs adjacent to two alternative PAX-5 promoters in a diffuse large-cell lymphoma. Proc Natl Acad Sci USA 93:6129, 1996
170. Iida S, Rao PH, Nallasivam P, Hibshoosh H, Butler M, Louie DC, Dyomin V, Chaganti RS, Dalla-Favera R: The t(9;14)(p13;q32) chromosomal translocation associated with lymphoplasmacytoid lymphoma involves the PAX-5 gene. Blood 88:4110, 1996
171. Stuart, ET, Haffner R, Oren M, Gruss P: (1995) Loss of p53 function through PAX-mediated transcriptional repression. EMBO J 14:5638, 1995
172. Grignani F, Ferrucci PF, Testa U, Talamo G, Fagioli M, Alcalay M, Mencarelli A, Grignani F, Peschle C, Nicoletti I: The acute promyelocytic leukemia-specific PML-RARα fusion protein inhibits differentiation and promotes survival of myeloid precursor cells. Cell 74:423, 1993
173. Inaba T, Inukai T, Yoshihara T, Seyschab H, Ashmun RA, Canman CE, Laken SJ, Kastan MB, Look AT: Reversal of apoptosis by the leukaemia-associated E2A-HLF chimaeric transcription factor. Nature 382:541, 1996
174. Dear TN, Colledge WH, Carlton MB, Lavenir I, Larson T, Smith AJ, Warren AJ, Evans, MJ, Sofroniew MV, Rabbitts TH: The Hox 11 gene is essential for cell survival during splenic development. Development 121:2909, 1995
175. Bernard M, Delabesse E, Novault S, Hermine O, MacIntyre EA: Anti-apoptotic effect of ectopic TAL1/SCL expression in a human leukemic T cell line. Cancer Res 58:2680, 1998
176. Rabbitts TH: Chromosomal translocations in human cancer. Nature 372:143, 1994
177. Hermeking H, Eick D: Mediation of c-myc-induced apoptosis by p53. Science 265:2091, 1994
178. Donehower LA, Harvey M, Slagle BL, McArthur MJ, Montgomery CA, Butel JS, Bradley A: Mice deficient for p53 are developmentally normal but are susceptible to spontaneous tumors. Nature 365:215, 1992
179. Harrington EA, Bennett MR, Fanidi A, Evan GI: c-myc-induced apoptosis in fibroblasts is inhibited by specific cytokines. EMBO J 13:3286, 1994
180. Smith KS, Jacobs Y, Chang CP, Cleary ML: Chimeric oncoprotein E2a-Pbx 1 induces apoptosis of hematopoietic cells by a p53-independent mechanism that is suppressed by bcl-2. Oncogene 14:2917, 1997
181. Reed JC: Double identity for proteins of the bcl-2 family. Nature 387:773, 1997
182. Sachs L, Lotem J: Control of programmed cell death in normal and leukemic cells: New implications for therapy. Blood 82:15, 1993
183. Ashkenazi A, Dixit VM: Death receptors: Signaling and modulation. Science 281:1305, 1998
184. Banin S, Moyal L, Shieh S-Y, Taya Y, Anderson CW, Chessa L, Smorodinsky NI, Prives C, Reiss Y, Shiloh Y, Ziv Y: Enhanced phosphorylation of p53 by ATM in response to DNA damage. Science 281:1674, 1998
185. Canman CE, Lim D-S, Cimprich KA, Taya Y, Tamai K, Sakaguchi K, Appella E, Kastan MB, Siliciano JD: Activation of the ATM kinase by ionizing radiation and phosphorylation of p53. Science 281:1677, 1998
186. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC: Regulation of cell death protease caspase-9 by phosphorylation. Science 282:1318, 1998
187. Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS, Anderson MJ, Arden KC, Blenis J, Greenberg ME: Akt promotes cell survival by phosphorylating and inhibiting a forkhead transcription factor. Cell 96:857, 1999
188. Willis TG, Jadayel DM, Du M-Q, Peng H, Perry AR, Abdul-Rauf M, Price H, Karran L, Majekodumni O, Wlodarska I, Pan L, Crook T, Hamoudi R, Isaacson DG, Dyer MJS: Bc110 is involved in t(1:14)(p22;q23) of MALT B cell lymphoma and mutated in multiple tumor types. Cell 96:35, 1999
189. Earnshaw WC: A cellular poison cupboard. Nature 397:387, 1999